Gold prices edge higher on raised Fed rate cut hopes
Investing.com - Cyclacel reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Cyclacel announced earnings per share of $-0.420 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.515 on revenue of $0.00.
Cyclacel 's are down 29.95% and is trading at $1.180 , still down 78.89% from its 52 week high of $5.59 set on Wednesday, November 10, 2021.
Cyclacel follows other major Healthcare sector earnings this month
Cyclacel's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar